| Code | CSB-RA024134MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to NXI-101, specifically targeting TPT1 (Tumor Protein Translationally-Controlled 1), also known as TCTP or fortilin. TPT1 is a highly conserved multifunctional protein involved in critical cellular processes including cell growth, proliferation, apoptosis regulation, and cellular stress responses. It functions as an anti-apoptotic factor and plays significant roles in tumorigenesis, with overexpression documented in various malignancies including breast, colon, and lung cancers. TPT1 is also implicated in allergic responses, neurodegenerative diseases, and metabolic disorders, making it an important target for understanding disease mechanisms and therapeutic development.
The reference antibody NXI-101 has been utilized in oncology and cell biology research to investigate TPT1's role in cancer progression, drug resistance, and cell survival pathways. This biosimilar antibody provides researchers with a reliable tool for studying TPT1 expression patterns, protein-protein interactions, and its involvement in cellular signaling cascades. It supports investigations into tumor biology, therapeutic target validation, and the molecular mechanisms underlying TPT1-mediated cellular functions.
There are currently no reviews for this product.